1-6 of 6
Daniel W. Robbins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Deyi Zhang, Hailey M. Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan Gajewski, Matthew C. Clifton, Stephanie Yung, Daniel W. Robbins, Mehdi Pirooznia, Sigrid S. Skånland, Erika Gaglione, Maissa Mhibik, Chingiz Underbayev, Inhye E. Ahn, Clare Sun, Sarah E. M. Herman, Mark Noviski, Adrian Wiestner
Journal: Blood
Blood (2023) 141 (13): 1584–1596.
https://doi.org/10.1182/blood.2022016934
Published: 2023
Includes: Supplemental data
Journal Articles

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Skye Montoya, Jessie Bourcier, Meghan C. Thompson, Mark Noviski, May Tan, Eric Wang, Xiaoli Mi, Nivetha Brathaban, Carla Barrientos Risso, Daniel Tsai, Jordan Ye, Jacob Jahn, Gabriel Pardo, Lee Cabuhat, Ryan Notti, Alejandro Pardo, Maurizio Affer, Stephanie Yung, James Luliano, Janine Powers, Daniel W Robbins, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M. Rhodes, Andrew D. Zelenetz, Lindsey E. Roeker, Hao Lu, Adam Linley, Anthony R. Mato, Omar Abdel-Wahab, Justin Taylor
Journal: Blood
Blood (2022) 140 (Supplement 1): 1811–1813.
https://doi.org/10.1182/blood-2022-163268
Published: 2022
Journal Articles

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

Daniel W Robbins, Mark Noviski, Ryan Rountree, May Tan, Nivetha Brathaban, Timothy Ingallinera, Dane E Karr, Aileen Kelly, Zef Konst, Jun Ma, Austin Tenn-McClellan, Jenny McKinnell, Luz Perez, Cristiana Guiducci, Gwenn Hansen, Arthur Sands
Journal: Blood
Blood (2021) 138 (Supplement 1): 2251.
https://doi.org/10.1182/blood-2021-147473
Published: 2021
Journal Articles

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Daniel W Robbins, Aileen Kelly, PhD, May Tan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Ge Peng, Jeff Mihalic, Dahlia Weiss, Luz Perez, Jennifer Tung, Anna Kolobova, Sasha Borodovsky, PhD, Ryan Rountree, Austin Tenn-McClellan, Mark Noviski, Jordan Ye, Steve Basham, Timothy Ingallinera, Jenny McKinnell, Dane E Karr, Janine Powers, PhD, Cristiana Guiducci, PhD, Arthur Sands
Journal: Blood
Blood (2020) 136 (Supplement 1): 34.
https://doi.org/10.1182/blood-2020-141461
Published: 2020
Journal Articles

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Deyi Zhang, PhD, Hailey Harris, Aileen Kelly, PhD, Daniel W Robbins, May Tan, Timothy Ingallinera, Neil Bence, Arthur T Sands, Sivasubramanian Baskar, Sarah E. M. Herman, Adrian Wiestner, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 174.
https://doi.org/10.1182/blood-2019-126921
Published: 2019
Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Aileen Kelly, PhD, Daniel W Robbins, May Tan, Austin Tenn-McClellan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Luz Perez, Jennifer Tung, Anna Kolobova, Timothy Ingallinera, Jenny McKinnell, Dahlia Weiss, Mark Noviski, Jordan Ye, Ge Peng, Mario Cardozo, Jeff Mihalic, Steve Basham, Ryan Rountree, Dane E Karr, Neil Bence, Christoph W Zapf, Arthur T Sands
Journal: Blood
Blood (2019) 134 (Supplement_1): 3805.
https://doi.org/10.1182/blood-2019-129262
Published: 2019